Assess the risk of fetal chromosomal abnormalities using fewer invasive procedures.
We offer screening systems for aneuploidies that combine markers and assays for high detection rates with low numbers of false positives. Such screening early in pregnancy allows expectant parents to make timely medical management decisions.
Our first and second trimester prenatal screening assays support both laboratories and clinics, with automated platforms available for AutoDELFIA® and DELFIA Xpress®. Victor2 D™ together with DELFIA® kits allow measurement of assays using semi-automated means.
Our safe, non-invasive first trimester screening tests are based on biochemical markers from maternal serum and provide expectant parents with a risk assessment for trisomy 21, 13, and 18.
PerkinElmer aneuploidy and pre-eclampsia screening products are not available in the USA. Products may not be available in all countries. For information on availability, please contact your local representative.
AutoDELFIA® immunoassay system for prenatal screening is supported by the widest available range of prenatal analytes available on any platform. Reliable and easy to use AutoDELFIA instrument offers high quality results both for aneuploidy and pre-eclampsia risk assessment during pregnancy.
The VICTOR2™ D fluorometer is designed for all PerkinElmer diagnostic and screening assays based on either time-resolved fluorescence or prompt fluorescence. VICTOR2 D includes MultiCalc software for assay evaluation and quality control.
The DELFIA® and AutoDELFIA™ hAFP/Free hCGß Dual kits are for the simultaneous quantitative determination of human Alpha-fetoprotein (hAFP) and the free beta subunit of human Chorionic Gonadotrophin (Free hCGß) in maternal serum.